Bellus Health Inc

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates

LAVAL, Quebec--( BUSINESS WIRE )--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitivity indications, today reported its financial and operating results for the third quarter ended September 30, 2022.

BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights

LAVAL, Quebec--( BUSINESS WIRE )--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in two upcoming healthcare investor conferences.

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

Here is how Bellus Health (BLU) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.

Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that an abstract reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming CHEST Annual Meeting, being held in Nashville, Tennessee from October 16-19, 2022. Poster Prese

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting

BELLUS Health intends to initiate two phase 3 studies in Q4 of 2022; these will be CALM-1 and CALM-2 studies using BLU-5937 for treatment of patients with refractory chronic cough. Final results from the phase 3 CALM-1 and CALM-2 studies using BLU-5937 for treatment of patients with refractory chronic cough are expected 2nd half of 2024.

Bellus: Expected Phase 3 Start Makes This A Long-Term Play

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference. Presentation Details:

BELLUS Health to Present at the H.C. Wainwright Global Investment Conference

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming European Respiratory Society (“ERS”) International Congress 2022, being held in Barcelona,

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today reported its financial and operating results for the second quarter ending June 30, 2022. “BELLUS remains committed to bringing BLU-5937, our P2X3 antagonist product candidate, to patients burdened by RCC. This

BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 16,540,541 common shares at a price to the public of US$9.25 per common share. The total gross proceeds to the Company were US$153 million, before deducting the underwriting commissions and any expenses related to the Offering. Bellus has also g

BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States

Issuing new shares will leave it with plenty of money in the bank.

Why BELLUS Health Stock Fell Today

LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers and LifeSci Capital as lead manager (collectively, the “Underwriters”), relating to the public offering of 16,540

BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States

BELLUS Health Inc (NASDAQ: BLU) (TSX:BLU) has filed a preliminary prospectus supplement to its amended and restated short form base shelf prospectus dated December 14, 2021, amending and restating the short form base shelf prospectus dated December 23, 2020, in connection.

BELLUS Health Shares Slide On Public Offering Of Shares In Canada And US

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its amended and restated short form base shelf prospectus dated December 14, 2021, amending and restating the short form base shelf prospectus dated December 23, 2020 (the “A&R Base Prospectus”) in connection with a proposed public offering of its common shares (the “Offering”). The Supplement was

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, today announced a positive End-of-Phase 2 (“EOP2”) meeting with the U.S. Food and Drug Administration (“FDA”) and the details of the CALM Phase 3 program for BLU-5937, a highly selective, second generation P2X3 antagonist p

Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough

Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the William Blair Biotech Focus Conference. Presentation Details:  Event: Willia

BELLUS Health to Participate in the William Blair Biotech Focus Conference

We may be turning the page to a new chapter where small-cap stocks re-establish their supremacy.

This Small-Cap Innovator is Flying High

Does Bellus Health (BLU) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Bellus Health (BLU) is a Great Momentum Stock to Buy

Alkermes

Geron

Immunocore Holdings

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

Are Medical Stocks Lagging Bellus Health (BLU) This Year?

The average of price targets set by Wall Street analysts indicates a potential upside of 83.3% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See an 83% Upside in Bellus (BLU): Can the Stock Really Move This High?

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY from June 8-10,

BELLUS Health to Participate in the Jefferies Healthcare Conference

Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Bellus Health Inc Stock (BLU)